Wegener's granulomatosis: Ophthalmic manifestations and management

被引:117
作者
Pakrou, N
Selva, D
Leibovitch, I
机构
[1] Jules Stein Eye Inst, Div Orbital & Ophthalm Plast Surg, Los Angeles, CA 90095 USA
[2] Royal Adelaide Hosp, Dept Ophthalmol & Visual Sci, Adelaide, SA 5000, Australia
关键词
Wegener's granulomatosis; ocular; orbital; ophthalmic; eye; vasculitis;
D O I
10.1016/j.semarthrit.2005.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To provide an up-to-date and comprehensive review of Wegener's granulomatosis (WG) as a disease entity, focusing on the ophthalmic manifestations and management options. METHODS A search of Medline was undertaken between 1966 and 2005 regarding WG, systemic vasculitis, and the ocular manifestations of WG. Major ophthalmic and medical textbooks also were reviewed for content, as well as original references. RESULTS Involvement of ocular and orbital structures in patients with WG is common and may be a presenting feature. The ocular manifestations range from mild conjunctivitis and episcleritis to more severe inflammation with keratitis, scleritis, uveitis, and retinal vasculitis. Involvement of the nasolacrimal system and orbital tissues also can occur. Except for some cases of anterior segment inflammation, the ocular involvement will not respond to topical agents, but rather to systemic anti inflammatory and immunosuppressive regimens. Surgical intervention may be of value for obtaining tissue diagnosis, in achieving orbital decompression in cases of significant orbital disease with optic nerve compromise, or in cases of nasolacrimal duct obstruction. CONCLUSION WG is an important clinical entity that needs to be recognized early and treated appropriately. Ophthalmic manifestations are frequently encountered and can result in significant morbidity and even blindness. The management is challenging and often requires a multidisciplinary approach.
引用
收藏
页码:284 / 292
页数:9
相关论文
共 93 条
[1]  
Abdou NI, 2002, J RHEUMATOL, V29, P309
[2]   Inflammatory conditions of the eye associated with rheumatic diseases. [J].
Afshari N.A. ;
Afshari M.A. ;
Foster C.S. .
Current Rheumatology Reports, 2001, 3 (5) :453-458
[3]   Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis [J].
Albini, TA ;
Zamir, E ;
Read, RW ;
Smith, RE ;
See, RF ;
Rao, NA .
OPHTHALMOLOGY, 2005, 112 (10) :1814-1820
[4]  
ANDERSON G, 1992, Q J MED, V83, P427
[5]   Predicting mortality in systemic Wegener's granulomatosis: A survival analysis based on 93 patients [J].
Bligny, D ;
Mahr, A ;
Le Toumelin, P ;
Mouthon, L ;
Guillevin, L .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (01) :83-91
[6]   Infliximab improves endothelial dysfunction in systemic vasculitis - A model of vascular inflammation [J].
Booth, AD ;
Jayne, DRW ;
Kharbanda, RK ;
McEniery, CM ;
Mackenzie, IS ;
Brown, J ;
Wilkinson, IB .
CIRCULATION, 2004, 109 (14) :1718-1723
[7]  
Borruat F X, 1996, Curr Opin Ophthalmol, V7, P10, DOI 10.1097/00055735-199612000-00003
[8]   Graves ophthalmopathy [J].
Bradley, Elizabeth A. .
CURRENT OPINION IN OPHTHALMOLOGY, 2001, 12 (05) :347-351
[9]  
BULLEN CL, 1993, Q J MED, V90, P279
[10]   LIMITED FORMS OF ANGIITIS AND GRANULOMATOSIS OF WEGENERS TYPE [J].
CARRINGTON, CB ;
LIEBOW, AA .
AMERICAN JOURNAL OF MEDICINE, 1966, 41 (04) :497-+